RxSight, Inc. Reports Third Quarter 2026 Results
Globe Newswire•03/11/2026•16:05 ET
1
Key Highlights
- ➤Revenue $24.6 million, down 19% year over year amid competitive pressures
- ➤Net loss widened to $16.2 million, or $0.39 per share
- ➤Adjusted net loss reached $8.6 million, or $0.21 per share
- ➤Cash, equivalents and short-term investments totaled $254.7 million
- ➤Alcon collaboration delivered minimal third-quarter revenue; $60 million received
Expert Statements
Aziz Mottiwala, President and Chief Executive Officer of RxSight
“Since I joined last quarter, the team has moved quickly and accomplished a great deal in a short period of time. We have strengthened our commercial organization and leadership, made progress across key long-term growth initiatives, and taken decisive actions to align our cost structure with our priorities. While there is more work ahead, we remain focused on execution. Based on our progress, I am confident we are positioning our company for long-term success.”
ALISO VIEJO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended September 30, 2026.
Third Quarter 2026 Financial Highlights * Total revenue of $24.6 million primarily driven by 23,128 Light Adjustable Lens™ (LAL™) units * Cash, cash equivalents and short-term investments of $254.7 million as of September 30, 2026, including the $60 million received in the third quarter in connection with the Alcon collaboration Strategic Highlights
Get started
Create a free account to read the full story.